E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with acute myeloid leukemia (AML) and high risk for induction failure |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000886 |
E.1.2 | Term | Acute myeloid leukemia |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluation of tolerability and safety of escalating doses of clofarabine in combination with cytarabine and idarubicine in the therapy of previously untreated patients with AML and high risk for induction failure |
|
E.2.2 | Secondary objectives of the trial |
•Definition of the recommended dose level of the combination of clofarabine, cytarabine and idarubicine for upcoming phase III trials in the therapy of previously untreated patients with AML and high risk for induction failure •Evaluation of the efficacy of escalating doses of clofarabine in combination with cytarabine and idarubicine in the therapy of previously untreated patients with AML and high risk of induction failure
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients with newly diagnosed acute myeloid leukemia according to WHO classification and aged ≥ 18 years eligible for an intensive induction chemotherapy with high risk for induction failure and for whom currently no molecularly targeted therapy is available: • absence of a t(15;17), t(8;21), inv(16)/t(16;16) and the respective fusion transcripts PML-RARA, RUNX1-RUNX1T1 and CBFB-MYH11 • absence of an activating FLT3-mutation (FLT3-ITD or TKD - mutation) • absence of an NPM1 exon12 mutation 2. Written informed consent 3. No previous cytotoxic chemotherapy for the treatment of AML (exception: oral hydroxyurea for up to 5 days during screening/baseline to control hyperleukocytosis) 4. Adequate renal and hepatic functions as indicated by the following laboratory values: • Serum creatinine </= upper limit of normal (ULN) or glomerular filtration rate (GFR) > 60 mL/min/1.73 m2, respectively • Serum bilirubine </= 1.5 x ULN • Aspartate aminotransferase (AST/SGOT) /alanine aminotransferase (ALT/SGPT) </= 2.5 x ULN • Alkaline phosphatase (ALP) </= 2.5 x ULN 5. Capable of understanding the investigational nature, potential risks and benefits of the study 6. Women of childbearing potential must have a negative serum pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to start of IMP treatment 7. Female patients must meet one of the following criteria: • For female patients > = 50 years of age at the day of inclusion: Menopause since at least 1 year • Female patients < 50 years of age at the day of inclusion who meet all of the following criteria: • menopause since at least 1 year • serum FSH levels > 40 MIU/mL • serum estrogen levels < 30 pg/mL or negative estrogen test • 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral ovariectomy with or without hysterectomy • Correct use of two reliable contraception methods from the time of screening/baseline and during the study for a minimum of 90 days after the last administration of study medication. This includes every combination of a hormonal contraceptive (such as injection, transdermal patch, implant, cervical ring) or of an intrauterine device (IUD) with a barrier method (diaphragm, cervical cap, Lea contraceptive, femidom or condom) or with a spermicide. In case the patient takes hormone preparations for suppression of menstruation during the period of aplasia, a suitable and effective method of contraception has to be discussed with the investigator and used by the patient • General sexual abstinence from the time of screening/baseline, during the study until a minimum of 90 days after the last administration of study medication • Having only female sexual partners • Monogamous relationship with sterile male partner 8. Male patients must meet one of the following criteria: • 6 weeks after surgical sterilization by vasectomy • Correct use of two reliable contraception methods from the time of screening/baseline and during the study for a minimum of 90 days after the last administration of study medication. This includes every combination of a hormonal contraceptive (such as injection, transdermal patch, implant, cervical ring) or of an intrauterine device (IUD) with a barrier method (diaphragm, cervical cap, Lea contraceptive, femidom or condom) or with a spermicide. • General sexual abstinence from the time of screening/baseline during the study until a minimum of 90 days after the last administration of study medication • Having only male sexual partners • Monogamous relationship with sterile female partner |
|
E.4 | Principal exclusion criteria |
1. Current concomitant chemotherapy, radiation therapy or immunotherapy not defined in the study protocol 2. Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of oral hydroxyurea. The patient must have recovered from all non-hematological acute toxicities from any previous therapy 3. Participation in a clinical trial within 30 days before inclusion in this study or concurrent to this study. 4. Bleeding disorder independent of AML 5. Patients with uncontrolled systemic fungal, bacterial, viral or other infection (defined as persistent disease signs/symptoms without improvement despite appropriate antibiotics or other treatment) 6.Patients with clinically relevant heart disease such as: •History of acute myocardial infarction within the last 6 months •Heart failure NYHA grade III or IV due to myocardial infarction or other causes •Acute inflammatory heart disease •Unstable atrial fibrillation or other hemodynamically relevant arrythmias 7. HIV infection 8. Patients who have received cumulative doses of ≥ 360mg/m2 of doxorubicin or its equivalent to other anrthracyclines, e.g. 900mg/m2 of daunorubicin, 450mg of pegylated liposomal doxorubicin hydrochloride, 225mg/m2 idarubicin or 140mg/m2 mitoxantrone 9. Pregnant or lactating women 10. Any significant concurrent disease, illness, psychiatric disorder or history of serious organ dysfunction that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results 11. Diagnosis of another malignancy, unless the patient is disease-free for at least 3 years following the completion of curative intent therapy, with the following exceptions: • Myelodysplastic syndrome (MDS) in patients with AML after MDS according to the WHO classification • Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed. 12. Known hypersensitivity to any of the IMPs |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Maximal tolerable dose (MTD) of clofarabine in combination with cytarabine and idarubicine in the therapy of previously untreated AML and high risk for induction failure |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
MTD will be defined on the basis of the occurrence of dose-limiting toxicities (DLTs) measured within 14 days after start of the first induction cycle (max. 42 days after start of the first induction cycle in case of hematological DLTs) |
|
E.5.2 | Secondary end point(s) |
1. Rate of complete remission after two cycles of induction therapy 2. Relapse-free, event-free and overall survival 3. Blast reduction in the bone marrow after the first induction cycle 4. Duration of aplasia 5. Therapy-associated morbidity and mortality 6. Course of molecular and cytogenetic markers during chemotherapy 7. Fraction of patients who receive an alloSCT in CR1 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. 3 months 2. 2 years 3. max. 42 days after start of the first induction cycle 4. max. 42 days after start of the first induction cycle 5. 2 years 6. 3 months 7. 2 years |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Dose-finding study of clofarabine in combination with cytarabine and idarubicine |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |